Introduction: Human ovary is commonly the target of an autoimmune attack in cases of organ- or non-organ-specific autoimmune disorders. Hashimotos thyroiditis (HT) is likely to be associated with ovarian dysfunction and diminished ovarian reserve. The classical hormonal test assessing ovarian reserve as early follicular phase serum levels of FSH, inhibin B and estradiol (E2), which are interdependent, and the calculation of the number of antral follicles by transvaginal ultrasonography have some inconvenience in very young girls. Anti-Muellerian Hormone (AMH), a relatively new marker of the ovarian reserve. Serum AMH levels increase during the first two decades of female live and then decrease gradually with age, and the levels become undetectable after menopause.
The aim: The aim of the study was to assess the ovarian reserve in young women with HT using the evaluation as well classical hormone methods (FSH, E2, Inibin B) as a measurement of AMH.
Material and methods: There were 21 patients treated due to Hashimoto disease, median age 15.6 years, and 17 healthy age-matched controls included to the study. In the group of patients with HT, 8 patients have additional T1DM diagnosed, so they presented with type 3 autoimmune poliendocrinopathy (APS 3). In all participants FSH, LH, estrogens, PRL, SHBG, TSH, fT4, anti-TPO, AMH, and Inhibin-B, if possibly in 3-5th day of the menstruation cycle were measured.
Results: As well FSH, E2, and Inhibin-B, as AMH levels did not differ statistically between group of patients with HT and healthy controls. Moreover we did not find any differences regarding parameters assessing ovarian function and reserve between patients with only HT and those with APS 3. Moreover levels of LH, SHBG, PRL, and fT4 did not differ in patients with HT, including APS 3 than in controls. Only TSH levels were significantly higher in HT group than in the control group (P=0.02). BMI of HT patients did not differ statistically from BMI of healthy controls.
Conclusion: The results of our study did not indicate that young patients with HT, including those with APS 3 have impaired ovarian reserve or function.
27 - 29 Sep 2018
European Society for Paediatric Endocrinology